
Your patient read that CAR-T could "reset" their immune system. How do you explain what that means?
Sheila Behimehr, NP is back with Leila Khalili, NP of Hospital for Special Surgery for part two of the series. They cover why CAR-T which has been used in oncology for a number of year makes sense in rheumatology, why B cells are such a strong target in lupus, scleroderma, and myositis, and why it is not the right fit for every autoimmune disease.
Leila also breaks down what the early data shows and how her team talks with patients who arrive excited with questions about this new potential treatment currently being researched.
Then the practical side. How do patients find trials? What does it mean to live far from an academic center? Why can monitoring require staying close to the treatment site? Leila points to the resources that can help.
The big takeaway: CAR-T is promising, the data is moving fast, and early conversations help patients know what to expect.
Part two of three. Next up: the care teams and what comes next.
Fler avsnitt från "Rheumor Has It"



Missa inte ett avsnitt av “Rheumor Has It” och prenumerera på det i GetPodcast-appen.


